<DOC>
	<DOC>NCT01562600</DOC>
	<brief_summary>The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with non-steroidal anti-inflammatory drug (NSAID).</brief_summary>
	<brief_title>Nexium Capsules Non-steroidal Anti-inflammatory Drug (NSAID) Specific Clinical Experience Investigation</brief_title>
	<detailed_description>Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with NSAIDs</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Patients who are given NSAIDs for long terms to control pain due to disease such as rheumatoid arthritis and osteoarthritis, and given Nexium to suppress recurrence of gastric ulcer or duodenal ulcer. Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of SakitaMiwa classification on endoscopy) Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>NSAIDs</keyword>
	<keyword>Gastric ulcer or duodenal ulcer</keyword>
	<keyword>Nexium</keyword>
</DOC>